Business Context and Reporting Period
This Form 8-K Current Report was filed by MiMedx Group, Inc. on September 22, 2009. The filing discloses material definitive agreements, unregistered sales of equity securities, and significant changes to the company's executive leadership and Board of Directors effective September 22 and September 23, 2009.
Key Financial Metrics and Agreements
The filing details a new financing arrangement and executive compensation packages but does not provide consolidated revenue, profit, or cash flow statements for the period.
- Debt Financing: Entered into a Subscription Agreement with Chairman and CEO Parker H. Petit for a 5% Convertible Promissory Note. The Company may advance up to $500,000 for working capital needs until December 20, 2009.
- Debt Terms: The Note bears 5% annual interest, is due in full on December 20, 2009, and is convertible into Common Stock. The conversion price is based on a future private placement price or defaults to $0.60 per share.
- Equity Issuance: Issued a Warrant to Mr. Petit to purchase shares equal to two times the aggregate advances made, exercisable at the Conversion Price. The Warrant expires in 3 years.
- Executive Compensation:
- William C. Taylor (President and COO): $225,000 annual base salary and options for 750,000 shares.
- Michael J. Culumber (CFO): $150,000 annual base salary.
- Roberta McCaw (General Counsel/Secretary): $7,500 monthly retainer and options for 37,500 shares.
- Director Compensation: New directors receive a $20,000 annual retainer, meeting fees ($2,500 in-person/$500 telephonic), committee fees, and one-time options for 50,000 shares each.
Material Changes Versus Prior Period
The filing reports significant organizational changes rather than financial performance variances:
- Leadership Appointments: Appointment of William C. Taylor as President and COO; Michael J. Culumber as CFO (previously Acting CFO); and Roberta McCaw as General Counsel and Secretary.
- Board Expansion: Election of J. Terry Dewberry and Joseph G. Bleser as directors, with assignments to Audit, Nominating, and Compensation Committees.
- Shareholder Restrictions: Execution of a Right of First Refusal Agreement with Executive Vice President Matthew J. Miller and Veritas Trust, restricting the transfer of their shares for 60 months unless the Company is given the right to purchase them first.
Guidance, Outlook, and Risks
The filing does not contain forward-looking financial guidance or revenue outlooks. Key risks and contingencies identified include:
- Liquidity Needs: The $500,000 credit facility with the CEO indicates a need for working capital funding through December 2009.
- Dilution Risk: The issuance of the Warrant (2x the principal amount) and the conversion feature of the Note create potential for significant equity dilution depending on the Conversion Price.
- Unregistered Securities: The Note and Warrant were issued under Section 4(2) of the Securities Act and Rule 506 of Regulation D to accredited investors without general solicitation.
Investor Verification Checklist
- Verify the actual amount of principal advanced under the $500,000 credit facility with Parker H. Petit.
- Confirm the "Conversion Price" determination mechanism, specifically whether a private placement has been approved to set the price or if the $0.60 default applies.
- Review the vesting schedules and exercise prices for the stock options granted to new executives and directors.
- Assess the impact of the Right of First Refusal Agreement on the liquidity of shares held by Matthew J. Miller.
- Check subsequent filings for the utilization of the working capital line and any additional debt or equity issuances.